A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.

CONCLUSIONS: Our study demonstrates the feasibility, accuracy, and reproducibility of the GuardantOMNI ctDNA platform for quantifying bTMB from plasma samples. Using the new bTMB algorithm and an optimal bTMB cut-off of ≥20 mut/MB, high bTMB was predictive of clinical benefit with durvalumab + tremelimumab versus chemotherapy.
PMID: 33355200 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 22, 2020 Category: Cancer & Oncology Authors: Si H, Kuziora M, Quinn KJ, Helman E, Ye J, Liu F, Scheuring U, Peters S, Rizvi NA, Brohawn P, Ranade K, Higgs BW, Banks KC, Chand VK, Raja R Tags: Clin Cancer Res Source Type: research